What Moderna's 10-Q disclosed before the melanoma readout

This article examines Moderna’s 31 July 10-Q and what it disclosed before the reported melanoma readout. It does not independently verify the later clinical results, treatment efficacy or safety.

What the company was, on paper, three weeks earlier

Before the readout, Moderna was a company whose revenue had collapsed and whose cash was going out the door.

The half-year is starker: $534 million of revenue against a $2,125 million net loss, and $1,156 million of cash consumed by operations.

30 Jun 2026    31 Dec 2025
Cash and equivalents        $1,723M        $2,595M
Investments                 $5,187M        $5,540M
─────────      ─────────
Total                       $6,910M        $8,135M
−$1,225M in six months

The balance sheet describes a company with $6.9 billion of liquidity, falling by roughly $1.2 billion every six months.

The full-year balance sheet says the same thing from another direction. Moderna’s revenue fell 39.9% in fiscal 2025 while its inventory rose 30.8%, taking days of stock from 29 to 64 — one of 66 companies that sold less and stocked more that year. Only 22% of that inventory was finished goods.

The two sentences in the pipeline paragraph

Now the part that matters, and it is one paragraph of the same 10-Q.

On the cancer programme, Moderna wrote that intismeran autogene is in nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder and renal cell carcinoma, that the Phase 3 adjuvant melanoma study is fully enrolled, and then this:

We expect Phase 3 adjuvant melanoma data potentially in 2026.

The event that added $44 billion was disclosed as expected, in a routine quarterly filing, three weeks before it happened. It was not a secret. It was a scheduled possibility, sitting in a paragraph that most readers skip.

And four sentences earlier, in the same disclosure, is the other half of the picture:

Norovirus vaccine: Our Phase 3 safety and efficacy study of mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis.

One programme missed. Another was about to read out. Both were in the same paragraph, given the same weight, before the reported readout discussed here.

That is what a pipeline is. A filing will tell you the shape of the distribution; it will not tell you which way it lands.

Reading the routine paragraph is usually where the work is. We have set out how we check a single number against the source document, and the same habit applies to prose: the sentence that matters is rarely the one in the headline.

Moderna keeps half

The number most coverage skipped is in the collaboration note.

Merck exercised its option on the programme in September 2022 and paid a $250 million exercise fee. Under the agreement, “costs and any profits or losses [are] generally shared equally on a worldwide basis.” Moderna leads process development and manufacturing; Merck generally leads the clinical trials.

Six months to 30 Jun 2026     $198M
Six months to 30 Jun 2025     $203M
───────
Against a half-year net loss of $2,125M  →  9.3%

Two things follow, and they point in opposite directions.

The programme is not what is bankrupting Moderna — it costs the company under 10% of its losses, because Merck pays half. But the upside is halved by the same clause. Whatever this drug is eventually worth, Moderna’s claim on it is 50%.

What we cannot tell you, and why we are saying so

The July filing does not establish the later trial’s effect size, hazard ratio, safety profile or statistical design. Those require separate primary clinical disclosures.

What the record does contain is a company with $6.9 billion, losing $2.1 billion a half, that owns half of a drug which was flagged three weeks ago as due to read out — alongside another drug that had just missed.

Limits of this analysis

• The absence of an 8-K is not a criticism. Companies may disclose material information by press release and webcast under Regulation FD without filing an 8-K. The point is narrower: it is not in the public filing record, so we cannot check it.
• We have not read the trial data. Everything here about the melanoma result is what the filings anticipated, not what the result was.
• The norovirus miss is not the melanoma readout. They are different programmes and different probabilities. It is included because it sat in the same paragraph, not because it predicts anything.
• A 50% economic share is not a 50% share of value. Manufacturing rights, tax, and the timing of costs all move the answer, and the agreement has exceptions we have not seen.

Check it yourself

The 10-Q is linked below. The pipeline paragraph is in Management’s Discussion under the product programme headings; the melanoma sentence and the norovirus sentence are within a few lines of each other. The Merck terms are in the collaboration note under “Merck Participation Term,” and the share count is on the cover.

The filing history link shows what has and has not been filed — re-checked on 24 August 2026, still nothing since 12 August.

We have also linked the press coverage. It is there as the claim this article tests, not as evidence for it. If a figure here does not match a filing, tell us and it will be corrected on the article and on the corrections log, with the date.